Notice of allowance for patent application of RCD405 in Canada
Arcede Pharma announces that the patent application for RCD405 has been allowed by a formal notice of allowance from the Canadian Intellectual Property Office.The patent relates to new molecules with a certain structure that can be used to treat diseases characterized by airway contractions, e.g. COPD, asthma, inflammation and/or vasoconstriction, leading to for example high blood pressure (Canadian patent application No: 3,100,835, NOVEL BRONCHODILATING HETERO-LINKED AMIDES). After formal fees are paid, the patent will be granted, giving Arcede Pharma market exclusivity in Canada through